The Science of Cannabis Drug Testing
Cannabis drug tests are grounded in well-understood pharmacology. The science is clear on what tests measure, how THC moves through the body, and why detection windows vary so dramatically between people. What the science does not support is the central claim that most drug tests imply: that a positive result proves current impairment.
The Core Finding
Standard urine drug tests detect THC-COOH, an inactive metabolite — not THC itself. THC-COOH is pharmacologically inactive, produces zero psychoactive effects, and can remain detectable in the body for days to weeks after the effects of cannabis have worn off. This creates a fundamental disconnect between what tests measure and what they are commonly assumed to demonstrate.
The Six Things to Understand
This section breaks cannabis-testing pharmacology into six topics, each on its own page. If you only read one, start with the first.
Why This Matters
The science of cannabis drug testing is not obscure academic material. It directly affects millions of Americans every year who face workplace testing, probation, child custody disputes, sports eligibility, security clearances, and medical cannabis access. Decisions made on the basis of these tests often treat a positive result as evidence of impairment, misconduct, or disqualification — when the underlying pharmacology does not support that conclusion.
This is not an argument against drug testing. Employers, regulators, courts, and the military have legitimate interests in workplace safety, performance, and compliance. But those interests are best served by tests that measure what they claim to measure. The scientific literature is clear that metabolite-based testing measures past exposure, not current impairment. The two are different questions, and they require different tests to answer honestly.
Authoritative Sources
The material in this section draws from peer-reviewed pharmacology literature, federal agency documents (SAMHSA, DOT, NIDA), and research by the scientists most associated with cannabinoid pharmacokinetics — notably Dr. Marilyn Huestis, whose 2007 review in Chemistry & Biodiversity (PMID 17712819) remains the most-cited reference on THC pharmacokinetics in humans.